News Releases

Sesen Bio announced proposed merger with Carisma Therapeutics Combined company will focus on the advancement of Carisma’s development of engineered macrophages for the treatment of cancer and other serious disorders Transaction is expected to close in the next two to three months, subject to Sesen

Transaction to create a well-funded, clinical-stage biotechnology company advancing engineered macrophages for the treatment of cancer and other serious disorders Combined company expected to have approximately $180 million of cash, cash equivalents and marketable securities at close, including $30

  Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value Strong balance sheet of $161 million in cash, cash equivalents and marketable securities as of June 30, 2022 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug.

Company intends to seek a partner for further development of Vicineum Sesen Bio continues to focus on the assessment of potential strategic alternatives CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 18, 2022-- Sesen Bio (Nasdaq: SESN ) today announced that it has made the strategic decision to

Strong balance sheet of $170 million in cash and cash equivalents as of March 31, 2022 , expected to fund current operating plan into the fourth quarter of 2024 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2022-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2022-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has initiated a process to review strategic alternatives with the goal of

Participated in productive CMC and Clinical Type A Meetings with the FDA in the fourth quarter Type C Meeting with the FDA planned for March 28, 2022 Strong balance sheet with $163M in cash and cash equivalents as of December 31, 2021 expected to fund current operating plan into 2024 CAMBRIDGE,

Minori Rosales , M.D., Ph.D. Brings Over 15 Years of Clinical Experience Stephanie Vigue to Support Company’s Mission with Broad Corporate Finance Expertise CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 10, 2022-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein